PRECOMIN: PREdictive Value of COntrast voluMe to creatinINe Clearance Ratio

Sponsor
Guangdong Provincial People's Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT01400295
Collaborator
(none)
3,000
1
33
90.9

Study Details

Study Description

Brief Summary

To determine a relatively safe contrast media volume to creatinine clearance cut-off value to avoid contrast-induced nephropathy in patients following coronary angiography

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Contrast media volume to creatinine clearance (V/CrCl) ratios were obtained from consecutive consenting patients after coronary angiography. Receiver-operator characteristic (ROC) curves were used to identify the optimal sensitivity for the observed range of V/CrCl. The predictive value of V/CrCl for the risk of contrast-induced nephropathy was assessed using multivariate logistic regression.Subgroup analysis was performed on patients with creatinine clearance < 60 ml/min,diabetes,emergent angiography.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    3000 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Predictive Value of the Contrast Media Volume to Creatinine Clearance Ratio for the Risk of Contrast-Induced Nephropathy After Coronary Angiography
    Study Start Date :
    Dec 1, 2010
    Actual Primary Completion Date :
    Sep 1, 2013
    Actual Study Completion Date :
    Sep 1, 2013

    Arms and Interventions

    Arm Intervention/Treatment
    coronary angiography

    The investigators reviewed all consecutive patients who were undergoing coronary angiography

    Outcome Measures

    Primary Outcome Measures

    1. Contrast-Induced Nephropathy [48-72 h]

      Contrast-Induced Nephropathy was defined as an increase in serum creatinine of more than 0.5 mg/dl from the baseline within 48-72 h of contrast exposure

    Secondary Outcome Measures

    1. An early abnormal increase in serum creatinine [24h]

      An early abnormal increase in serum creatinine defined as an increase in serum creatinine of more than 0.5 mg/dl from the baseline within 24h of contrast exposure

    2. Major adverse clinical events [1 year]

      Major adverse clinical events: death, requiring renal replacement therapy, 2nd myocardial infarction,target revascularization,acute heart failure, mechanical ventilation,2nd angina,tachyarrhythmia,hypotension,intra-aortic balloon pump and stroke

    3. Major adverse clinical events [1month]

      Major adverse clinical events: death, requiring renal replacement therapy, 2nd myocardial infarction,target revascularization,acute heart failure, mechanical ventilation,2nd angina,tachyarrhythmia,hypotension,intra-aortic balloon pump and stroke

    4. An early abnormal increase in serum cystatin C [24h]

      An early abnormal increase in serum cystatin C was defined as an increase more than 10% from the baseline within 24h of contrast exposure

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • patients who agreed to stay in the hospital for 2-3 days after coronary angiography

    • provided written informed consent

    Exclusion Criteria:
    • pregnancy

    • lactation

    • intravascular administration of an contrast medium within the previous seven days

    • treatment with metformin,aminoglycosides,N-acetylcysteine (NAC),nonsteroidal anti-inflammatory drugs within the previous 48 h

    • intake of nephrotoxic drugs within the previous seven days

    • history of serious reactions to contrast mediums, severe concomitant disease renal transplantation , or end-stage renal disease necessitating dialysis

    • patients who died during coronary angiography

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Guangdong Cardiovascular Institute,Guangdong General Hospital Guangzhou Guangdong China 510080

    Sponsors and Collaborators

    • Guangdong Provincial People's Hospital

    Investigators

    • Study Chair: Jiyan Chen, MD, Guangdong Cardiovascular Institute,Guangdong General Hospital
    • Study Director: Yong Liu, MD, Guangdong Cardiovascular Institute,Guangdong General Hospital
    • Study Director: Yingling Zhou, MD, Guangdong Cardiovascular Institute,Guangdong General Hospital
    • Study Director: Ning Tan, MD, Guangdong Cardiovascular Institute,Guangdong General Hospital
    • Principal Investigator: Jianfang Luo, MD, Guangdong Cardiovascular Institute,Guangdong General Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Jiyan Chen, MD, Guangdong Provincial People's Hospital
    ClinicalTrials.gov Identifier:
    NCT01400295
    Other Study ID Numbers:
    • 20100917
    First Posted:
    Jul 22, 2011
    Last Update Posted:
    Sep 16, 2014
    Last Verified:
    Sep 1, 2014
    Keywords provided by Jiyan Chen, MD, Guangdong Provincial People's Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 16, 2014